Quest Diagnostics (DGX) Tops Q4 EPS by 7c

Quest Diagnostics (NYSE: DGX) reported Q4 EPS of $1.98, $0.07 better than the analyst estimate of $1.91. Revenue for the quarter came in at $2.33 billion versus the consensus estimate of $2.26 billion.

GUIDANCE:

Quest Diagnostics sees FY2023 EPS of $8.40-$9.00, versus the consensus of $8.69. Quest Diagnostics sees FY2023 revenue of $8.83-9.03 billion, versus the consensus of $9.13 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• RCM Technologies (RCMT) Tops Q2 EPS by 17c